We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
+$49.5M
Cap. Flow %
1.9%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.12%
2 Miscellaneous 3.14%
3 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$7.72B
$27.4M 1.05%
581,944
-111,900
-16% -$5.32M
COR icon
27
Cencora
COR
$61.7B
$26.7M 1.03%
330,687
-45,813
-12% -$3.93M
MOH icon
28
Molina Healthcare
MOH
$10.8B
$23.5M 0.9%
402,541
-135,360
-25% -$7.46M
A icon
29
Agilent Technologies
A
$42.4B
$21.7M 0.83%
459,950
-35,500
-7% -$1.66M
MDCO
30
DELISTED
Medicines Co
MDCO
$21.3M 0.82%
564,438
-139,800
-20% -$5.27M
NVS icon
31
Novartis
NVS
$263B
$19.6M 0.76%
277,661
+87,829
+46% +$6.4M
ENDP
32
DELISTED
Endo International plc
ENDP
$18.4M 0.71%
914,548
+628,200
+219% +$12.5M
CPHD
33
DELISTED
Cepheid Inc
CPHD
$17.6M 0.68%
333,590
– –
PBYI icon
34
Puma Biotechnology
PBYI
$477M
$17.4M 0.67%
260,200
– –
CNC icon
35
Centene
CNC
$33.4B
$17.2M 0.66%
513,000
+273,000
+114% +$9.48M
IBB icon
36
iShares Biotechnology ETF
IBB
$10.3B
$16.7M 0.64%
173,010
– –
UHS icon
37
Universal Health Services
UHS
$10.4B
$16.6M 0.64%
134,680
– –
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$31.9B
$16.5M 0.64%
243,995
– –
GSK icon
39
GSK
GSK
$100B
$15.5M 0.6%
287,200
-60,160
-17% -$3.3M
AZN icon
40
AstraZeneca
AZN
$251B
$15.2M 0.59%
231,900
-55,100
-19% -$3.6M
IDXX icon
41
Idexx Laboratories
IDXX
$40.2B
$14.9M 0.57%
132,352
– –
OHI icon
42
Omega Healthcare
OHI
$14.3B
$14.6M 0.56%
413,116
– –
TMO icon
43
Thermo Fisher Scientific
TMO
$237B
$13.7M 0.53%
86,395
– –
HZNP
44
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$13.6M 0.52%
749,900
– –
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
$13.3M 0.51%
200,000
– –
ZBH icon
46
Zimmer Biomet
ZBH
$18.8B
$13.3M 0.51%
105,369
– –
SRPT icon
47
Sarepta Therapeutics
SRPT
$2.19B
$13.1M 0.51%
+214,100
New +$6.47M
DHC
48
Diversified Healthcare Trust
DHC
$1.89B
$13.1M 0.5%
575,054
-95,450
-14% -$2.11M
MPT
49
Medical Properties Trust
MPT
$2.11B
$12.4M 0.48%
839,217
-81,176
-9% -$1.23M
CTMX icon
50
CytomX Therapeutics
CTMX
$586M
$11.9M 0.46%
756,090
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.